IL6 and atherosclerosis: These agents also suppress inflammatory pathways by reducing pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) [22], thus stabilizing atherosclerotic plaques and slowing atherosclerosis progression [22].